| Literature DB >> 24223781 |
Yang Chen1, Xianxiang Xin, Jie Li, Jianfeng Xu, Xiaoxiang Yu, Tianyu Li, Zengnan Mo, Yanling Hu.
Abstract
Prostate cancer (PCa) is a global disease causing large numbers of deaths every year. Recent studies have indicated the RTK/ERK pathway might be a key pathway in the development of PCa. However, the exact association and evolution-based mechanism remain unclear. This study was conducted by combining genotypic and phenotypic data from the Chinese Consortium for Prostate Cancer Genetics (ChinaPCa) with related databases such as the HapMap Project and Genevar. In this analysis, expression of quantitative trait loci (eQTLs) analysis, natural selection and gene-based pathway analysis were involved. The pathway analysis confirmed the positive relationship between PCa risk and several key genes. In addition, combined with the natural selection, it seems that 4 genes (EGFR, ERBB2, PTK2, and RAF1) with five SNPs (rs11238349, rs17172438, rs984654, rs11773818, and rs17172432) especially rs17172432, might be pivotal factors in the development of PCa. The results indicate that the RTK/ERK pathway under natural selection is a key link in PCa risk. The joint effect of the genes and loci with positive selection might be one reason for the development of PCa. Dealing with all the factors simultaneously might give insight into prevention and aid in predicting the success of potential therapies for PCa.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24223781 PMCID: PMC3817240 DOI: 10.1371/journal.pone.0078254
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the subjects included in this analysis.
| case (n = 1417) | control (n = 1008) | |
| Age (mean±SD) | 71.3±8.1 | 62.1±1.0 |
| Classification of PSA, n (%) | ||
| ≤4.0 | 55 (4.1%) | 965 (95.9%) |
| >4.0, <10 | 186 (13.9%) | 32 (3.2%) |
| ≥10 | 1098 (82.0%) | 9 (0.9%) |
| Missing | 78 | 2 |
| Gleason score, n (%) | ||
| <7 | 355 (26.3%) | NA |
| ≥7 | 993 (73.7%) | NA |
| Missing | 69 | NA |
| Clinical stage, n (%) | ||
| Stage (0, I, II) | 727 (59.7%) | NA |
| Stage (III, IV) | 490 (40.3%) | NA |
| N-stage(0) | 759 (67.3%) | NA |
| N-stage(≥1) | 369 (32.7%) | NA |
| M-stage(0) | 810 (64.8%) | NA |
| M-stage(≥1) | 440 (35.2%) | NA |
• all the information are collected at the moment of the cases diagnosed and controls recruited.
Results of gene-based pathway associated analysis with Adaptive rank truncated product (ARTP) method.
| Genes |
| Pathway |
| IGF1R | 0.05919 |
|
|
|
| |
|
|
| |
| CCND3 | 0.12108 | |
|
|
| |
| EGFR | 0.12999 | |
| PDGFD | 0.95091 | |
|
|
| |
| MAPK3 | 0.18758 | |
|
|
| |
|
|
| |
|
|
| |
| CCND2 | 0.58054 | |
| SOS1 | 0.22248 | |
| PDGFC | 0.20288 | |
| VEGFA | 0.4960 | |
| EGF | 0.56194 | |
| MAP2K1 | 0.33257 | |
| FLT4 | 0.43616 | |
| MET | 0.12829 | |
| BCL2 | 0.84392 | |
| IGF1 | 0.48125 | |
| MAPK1 | 0.97740 | |
| PDGFB | 0.51325 | |
| HGF | 0.15429 | |
| FYN | 0.95261 | |
| BRAF | 0.37986 | |
| GRB2 | 0.83362 | |
| VEGFC | 0.44556 | |
| SOS2 | 0.64114 | |
| BAD | 0.36066 | |
| PDGFRB | 0.79392 | |
| PDGFRA | 0.67403 | |
| HRAS | 0.37000 | |
| VEGFB | 0.22218 | |
| XIAP | 0.23878 | |
| SHC1 | 0.56594 | |
| BIRC3 | 0.75293 | |
| ELK1 | 0.58034 |
• all the results were calculated by ARTP method with the significant SNPs (P<0.05) in the loci-level associated analysis collected.
• the significant P values were marked in the bold.
The SNPs which were identified to be significances (P<0.05) in the loci-level associated analysis and under nature positive selection (|iHS|>1.65).
| CHR | SNP | Gene | OR | L95 | U95 | P | iHs_ASN | iHs_CEU | iHs_YRI | Gene_ASN | Gene_CEU | Gene_YRI |
| 7 | rs11238349 | EGFR | 0.766 | 0.6078 | 0.9653 | 0.02387 | −2.751 | −1.532 | NA |
| ||
| 7 | rs2302535 | EGFR | 0.7708 | 0.6121 | 0.9707 | 0.02693 | −2.725 | −1.503 | NA |
| ||
| 7 | rs12535578 | EGFR | 0.7809 | 0.6206 | 0.9826 | 0.03486 | −2.723 | −1.734 | NA |
| ||
| 7 | rs3800827 | EGFR | 0.801 | 0.6543 | 0.9806 | 0.03158 | −2.538 | −1.594 | NA |
| ||
| 7 | rs984654 | EGFR | 0.8001 | 0.6579 | 0.9731 | 0.02558 | −2.530 | −1.498 | NA |
| ||
| 7 | rs3735064 | EGFR | 0.7874 | 0.6429 | 0.9642 | 0.02077 | −2.498 | −1.635 | −1.003 |
| ||
| 7 | rs9642564 | EGFR | 0.8008 | 0.6535 | 0.9814 | 0.03226 | −2.498 | −1.635 | NA |
| ||
| 7 | rs11766798 | EGFR | 0.8016 | 0.6539 | 0.9826 | 0.0333 | −2.495 | −0.906 | NA |
| ||
| 7 | rs6978771 | EGFR | 0.793 | 0.6476 | 0.971 | 0.02475 | −2.429 | −1.804 | NA |
| ||
| 7 | rs11773818 | EGFR | 0.8013 | 0.6663 | 0.9636 | 0.01856 | −2.171 | −0.908 | NA |
| ||
| 3 | rs9818046 | NA | 0.7656 | 0.6098 | 0.9612 | 0.0214 | −1.675 | −0.236 | 0.343 |
| ||
| 7 | rs3735062 | EGFR | 0.6426 | 0.4156 | 0.9934 | 0.04664 | −1.653 | NA | NA |
| ||
| 7 | rs17172432 | EGFR | 0.673 | 0.525 | 0.8626 | 0.001768 | 2.967 | −0.416 | 0.457 |
| ||
| 7 | rs17172434 | EGFR | 0.6899 | 0.5297 | 0.8984 | 0.005871 | 2.850 | NA | 0.020 |
| ||
| 15 | rs6494584 | NA | 0.8549 | 0.7465 | 0.979 | 0.02338 | 2.233 | NA | −0.050 |
| ||
| 11 | rs7115260 | NA | 0.1387 | 0.02398 | 0.8024 | 0.0274 | 2.161 | 1.318 | 1.331 | |||
| 3 | rs2255648 | MKRN2 | 0.7628 | 0.6026 | 0.9655 | 0.02431 | 2.104 | 1.158 | 0.365 |
| ||
| 3 | rs1542848 | MKRN2 | 0.6941 | 0.5314 | 0.9068 | 0.007408 | 2.008 | 0.323 | −0.056 |
| ||
| 7 | rs17172438 | EGFR | 0.6003 | 0.4153 | 0.8678 | 0.006644 | 1.912 | −0.424 | −0.453 |
| ||
| 7 | rs17172436 | EGFR | 0.6598 | 0.4401 | 0.989 | 0.04405 | 1.912 | NA | 0.769 |
| ||
| 7 | rs3735063 | EGFR | 0.638 | 0.4246 | 0.9586 | 0.0305 | 1.908 | NA | NA |
| ||
| 3 | rs2633442 | MKRN2 | 0.7542 | 0.5822 | 0.9771 | 0.03272 | 1.893 | 0.850 | −0.811 |
| ||
| 3 | rs2442802 | MKRN2 | 0.7669 | 0.5926 | 0.9925 | 0.04365 | 1.893 | 0.850 | −0.811 |
| ||
| 7 | rs10488140 | EGFR | 0.7337 | 0.5399 | 0.997 | 0.04782 | 1.824 | −0.463 | −0.139 |
| ||
| 16 | rs2005219 | BOLA2 | 0.7858 | 0.6737 | 0.9166 | 0.002144 | 1.750 | 0.874 | 0.211 | |||
| 3 | rs2454431 | NA | 0.743 | 0.5746 | 0.9608 | 0.02354 | 1.722 | −0.017 | −1.581 |
| ||
| 7 | rs6958497 | EGFR | 2.64 | 1.119 | 6.227 | 0.02663 | 1.647 | NA | 0.962 |
|
• the “+” stands for the genes under positive selection.
The condition of genes in the RTK/ERK pathway under positive selection among three different populations.
| Gene | CEU | YRI | ASN |
| PDGFC | 0.12713 | 0.643733 | 0.114897 |
| PDGFD | 0.257203 | 0.406681 | 0.753926 |
| IGF1 |
| 0.54597 | 0.503402 |
| HGF | 0.448157 | 0.273572 | 0.420436 |
| EGFR | 0.527316 | 0.889825 |
|
| PDGFRA | 0.633894 | 0.889825 | 0.60804 |
| ERBB2 | 0.633894 | 0.040607 | 0.60804 |
| IGF1R | 0.632913 | 0.755287 | 0.607936 |
| PDGFRB | 0.448157 | 0.761058 | 0.361076 |
| FLT1 | 0.62966 | 0.641741 | 0.271252 |
| FLT4 | 0.12713 | 0.889825 | 0.755444 |
| KDR | 0.787049 | 0.761058 | 0.755444 |
| MET | 0.633894 | 0.185004 | 0.755444 |
| SHC1 | 0.633894 | 0.35688 |
|
| GRB2 |
| 0.240116 |
|
| SOS1 | 0.258804 | 0.643733 | 0.503402 |
| HRAS | 0.787049 | 0.35688 | 0.755444 |
| RAF1 | 0.633894 | 0.273572 |
|
| MAP2K1 | 0.528917 |
| 0.420436 |
| BAD | 0.187752 | 0.273572 | 0.420436 |
| BCL2 | 0.231643 | 0.753039 | 0.270781 |
| MAPK3 | 0.633894 | 0.761058 | 0.420436 |
| MAPK1 | 0.633894 | 0.13459 | 0.60804 |
| ELK1 | NA | NA | NA |
| BRAF | 0.386864 | 0.209827 | 0.755444 |
| PTK2 |
| 0.27204 | 0.755444 |
| FYN | 0.210111 | 0.207937 | 0.60626 |
| SOS2 | 0.633894 | 0.312085 | 0.60804 |
| CCND1 | 0.386864 | 0.761058 | 0.214353 |
| CCND2 | 0.633894 | 0.643733 | 0.503402 |
| CCND3 | 0.528917 | 0.761058 | 0.114897 |
| BIRC2 | 0.528917 | 0.406732 | 0.60804 |
| BIRC3 | 0.528917 | 0.406732 | 0.60804 |
| XIAP | NA | NA | NA |
| EGF | 0.12713 | 0.273572 | 0.138348 |
| PDGFA | NA | NA | NA |
| PDGFB | 0.633894 | 0.406732 |
|
| VEGFA | 0.633894 | 0.468536 | 0.755444 |
| VEGFB | 0.169059 | 0.35688 | 0.420436 |
| VEGFC | 0.448157 | 0.761058 | 0.19174 |
• On the basis of the haplotter the positive selections were estimated for almost all the genes in the pathway in which P<0.1 was looked as the threshold.
• the significant P values were marked in the bold.
The characteristics of the positive loci in our studies with different analysis.
| SNP | Gene | Allele | Genotype | loci_iHS | gene_iHS | loci_based | gene_based | cis-eQTL | ||
| mm | Mm | MM | ||||||||
| rs11238349 | EGFR | A/G | 21 | 362 | 1834 | −2.751 | 0.07925 | 0.02387 | 0.12999 | 0.013(CEU) |
| rs17172438 | EGFR | T/C | 1 | 151 | 2273 | 1.912 | 0.07925 | 0.006644 | 0.12999 | 0.0382(YRI) |
| rs984654 | EGFR | C/T | 36 | 540 | 1848 | −2.530 | 0.07925 | 0.02558 | 0.12999 | 10-4(LCL) |
| rs11773818 | EGFR | T/C | 45 | 620 | 1759 | −2.171 | 0.07925 | 0.01856 | 0.12999 | 0.0675(fibroblast)/<10−4(LCL) |
| rs17172432 | EGFR | T/C | 9 | 353 | 1991 | 2.967 | 0.07925 | 0.001768 | 0.12999 | 0.0424(JPT) |
• m, minor allele; M, major allele.
• the iHS values are referred to be the ASN population.
• the eQTL is based on the Sanger with three different databases: HapMapIII, MuTHER healthy female twins and Geneva GenCord individuals.